GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » Total Equity

Inovio Pharmaceuticals (FRA:GBM) Total Equity : €86.89 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Inovio Pharmaceuticals Total Equity?

Inovio Pharmaceuticals's total equity for the quarter that ended in Mar. 2024 was €86.89 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Inovio Pharmaceuticals Total Equity Historical Data

The historical data trend for Inovio Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Total Equity Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.87 379.06 353.71 209.91 107.61

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 186.07 156.33 129.46 107.61 86.89

Inovio Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Inovio Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=156.762-49.153
=107.61

Inovio Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=118.785-31.898
=86.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (FRA:GBM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » Total Equity
Comparable Companies
MGNX AGEN XERS EPIX RVNC INZY PSTX CRMD XOMA MRSN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
INO:USA INO:Mexico
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Website
https://www.inovio.com
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals (FRA:GBM) Headlines

No Headlines